Annual report 2022

— Business review — Healthcare review

medmix Drug Delivery: Re-Vario™ A

Healthcare review

Our Healthcare business area comprises the Dental, Drug Delivery and Surgery segments. They develop, produce and market a broad range of products, such as dispensers, cartridges, syringes, needles, mixers and tips for dental applications, syringes, pen injectors and autoinjectors for subcutaneous delivery of biomaterials, and delivery devices for bone repair and tissue treatment.

Key figures

millions of CHF






Change in +/–%


+/–% adjusted 2)


+/–% organic 3)

Revenue Dental











Revenue Drug Delivery











Revenue Surgery











Total revenue Healthcare 1)






















Business area cost of goods sold











Business area gross profit











Business area gross profit margin











1) Revenue from external customers.

2) Adjusted for currency effects.

3) Adjusted for acquisition and currency effects.

Revenue by market segment


Revenue by market segment


Dental – Strong growth after full recovery from the pandemic slowdown

Revenue in our Dental segment was up to CHF 125.1 million in 2022 compared to CHF 116.3 million in 2021, an increase of 5.8% year-on-year reflecting the high order backlog in the beginning of 2022 as the markets recovered from the pandemic slowdown. Business is now at pre-pandemic levels even though dental occupancy rates have not yet recovered in all markets, especially the US.

Our Dental segment offers innovative dental delivery solutions and value-added services with a view to providing an ideal user experience. Key to our growth ambition in Dental is our focus on product expansion, the development of new products for adjacent applications and the entry into new markets.


Our MIXPACTM original two- and one-component system solutions are meticulously matched to ensure safe and reliable compatibility between all components as well as an efficient time-saving workflow.

We conducted numerous collaborative development and ideation meetings together with our customers in 2022. As a result, we grew our product development pipeline substantially. The resulting first launches are already planned for Q1 2023.

Our growth in this area is fueled by a focus on innovation, sustainability, the creation of new products, and numerous collaborative developments. As we look towards the future, innovation remains a top priority, fueling our commitment to delivering game-changing solutions and continued growth.

Drug Delivery – Profiting from key trends and new products

The revenue in our Drug Delivery market segment was CHF 47.0 million, growing by an impressive 21.4% compared to the 2021 revenue of CHF 40.8 million.

In May 2022, medmix launched PiccoJectTM, an innovative, highly compact and customizable two-step autoinjector, a small device designed for high performance. This new product will address a market projected to grow by more than 10% CAGR due to strong growth in biologics and biosimilars. In December 2022, we signed the first customization order for PiccoJect, signaling its strong attractiveness for pharma customers.

In 2022, medmix Drug Delivery (Haselmeier™) and the AARDEX® Group announced joining forces to improve the self-administration of injectable drugs in clinical trials. Given the AARDEX Group’s and Haselmeier´s decades long experience in the pharma industry, the collaboration comes naturally. It complements the offering of both companies in clinical testing. This evidence-based approach can make the difference between failed and successful clinical trials.

Surgery – Strong growth from the tissue bank market

In 2022, our Surgery segment delivered revenue of CHF 12.8 million, a 1.3% increase over the prior year revenue. The segment recovered strongly from the pandemic-induced reduction in elective surgeries in 2021. The year-on-year growth rate was negatively impacted by overstocking by a large customer in 2021 even though the tissue bank revenue recorded impressive growth rates of 52.3%.

Our Surgery segment is specialized in the design and production of surgical delivery devices of biomaterials for trauma, bone repair and tissue regeneration. Its portfolio includes the new Ergosyringe for dental and maxillofacial surgeries. We continued to focus on growing our business by collaborating with tissue banks and large original equipment manufacturer (OEM) customers on designing and developing tailormade solutions for managing their biomaterials. In 2022, we signed a co-development agreement with a major global OEM that will support our growth for the next years. For the benefit of US customers of all three segments in Healthcare, we signed a lease in January 2022 for a new production facility in Atlanta, USA. We will invest CHF 20 million and create 200 jobs in this 300,000 square feet facility. Commercial production should commence towards the end of 2023.

Definition of alternative performance measures (APMs):
For the definition of the alternative performance measures, please refer to the chapter alternative performance measures.